Nationally estimated annual number of prescriptions dispensed for the top 10 newly approved opioid analgesic brand products (left axis, bar graph) and the combined market share of all newly approved opioid analgesic brand products (right axis, line graph) in the U.S. outpatient retail pharmacy setting from 1997 through 2015. Source: IQVIA, National Prescription Audit. Individual brand products represent the brand opioid analgesics dispensed in 2015 that were introduced into the market from 1997 to 2015. Only brand utilization is shown—does not include generic utilization. Solid line represents the combined market share for all brand products approved between 1997 and 2015, out of the total opioid analgesic market. Opana ER includes original formulation (approved 2006) and reformulation (approved 2011). OxyContin includes original formulation (approved 1995) and reformulation (approved 2010). Utilization excludes injectable formulations, opioid-containing cough/cold products, and opioid-containing medication assistance therapy products. *All Others includes all brand opioid analgesic products approved between 1997 and 2015 that are not individually shown. ER = extended-release formulation.